|
Workforce development has become a strategic priority for many
corporations in India and a central occupation of their
executives.
Multinational corporations are searching for means to broaden
their capacity for drug development while decreasing costs.
Pharmaceutical firms in India and China are increasingly forging
partnerships with these corporations to gain revenue and to
develop their own expertise. These relationships largely appear to
be symbiotic.
As a result of the movement of R&D to their countries, Indian and
Chinese scientists are rapidly developing the ability to innovate
and create their own intellectual property. Several firms in India
and China are performing advanced research and development and are
moving into the highest-value segments of the pharmaceutical
global value chain.
What is noteworthy is that most of the advances in R&D in India
and China happened over the last decade with the greatest momentum
being built over the last five years.
|